JWCA
CRSP icon

J.W. Cole Advisors’s CRISPR Therapeutics CRSP Stock Holding History

J.W. Cole Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,182
Closed -$266K – 677
2020
Q3 		$266K Buy
+3,182
New +$282K 0.02% 582

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

J.W. Cole Advisors's CRSP Position: Q4 2020 in Review

J.W. Cole Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 3,182 shares — an estimated $266K sold.

J.W. Cole Advisors first reported a position in CRSP in Q3 2020 and held it in 1 quarter. The position peaked at $266K in Q3 2020. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • J.W. Cole Advisors reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
  • J.W. Cole Advisors sold 3,182 CRISPR Therapeutics shares in Q4 2020, an estimated $266K.
  • J.W. Cole Advisors first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 1 quarter.
  • J.W. Cole Advisors's CRISPR Therapeutics position peaked at $266K in Q3 2020.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on J.W. Cole Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.